Specialty medical injectable drug program, requirements and drug policy updates
New specialty medical injectable updates and requirements announced.
June 27, 2023
Review the following tables to determine changes to our specialty medical injectable drug programs.
SPECIALTY MEDICAL INJECTABLE DRUGS ADDED TO REVIEW AT LAUNCH
| Drug Name | UnitedHealthcare Commercial | Treatment Uses |
Elfabrio® (pegunigalsidase alfa-iwxj) |
X | For the treatment of adults with Fabry disease. |
QalsodyTM (tofersen) |
X | For the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. |
Review the UnitedHealthcare Commercial Plan Review at Launch Medication List.
For questions, please contact your broker or UnitedHealthcare representative.
